Current Gastroenterology Reports

, Volume 1, Issue 6, pp 470–475

New biologic agents: A critical appraisal

  • Bruce E. Sands

DOI: 10.1007/s11894-999-0005-7

Cite this article as:
Sands, B.E. Curr Gastroenterol Rep (1999) 1: 470. doi:10.1007/s11894-999-0005-7


Approval of infliximab for treatment of Crohn's disease in late 1998 was a landmark event in medical therapy for inflammatory bowel disease. This agent was the first of many promised biologic response modifiers investigated in the last half decade, a result of progress in recombinant and monoclonal technologies and improvements in large-scale production of biologic agents. The notable efficacy of infliximab also sets a benchmark against which future biologic agents might be compared. Although it will be many years until active comparisons of these agents are made through clinical trials, sufficient clinical data is now available for critical appraisal of the potential and reality of these agents.

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Bruce E. Sands
    • 1
  1. 1.Gastrointestinal Unit and Center for the Study of Inflammatory Bowel DiseaseMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations